In
a statement, the company said it increased its production capacity
by 50% across its eight hydroxychloroquine manufacturing sites
worldwide, adding it was on track to quadruple it by the summer.
"Sanofi is calling for coordination among the entire
hydroxychloroquine chain worldwide to ensure the continued supply of
the medicine if proven to be a well-tolerated and effective
treatment in COVID-19 patients", it said.
(Reporting by Sudip Kar-Gupta and Benoit Van Overstraeten; Editing
by Frances Kerry)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |